The University of Texas MD Anderson Cancer Center Board of Visitors (BOV), a nonfiduciary, appointed advisory board of volunteers who advance the institution’s mission to end cancer, marks the beginning of Fiscal Year 2019 with nine new members, effective Sept. 1:
Combination immunotherapy shrank melanoma that has spread to the brain in more than half of the patients in a clinical trial reported in the...
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended...
The University of Texas MD Anderson Cancer Center again has been ranked No. 1 for cancer care by U.S. News & World Report’s annual “Best Hospitals” survey. Since the survey began in 1990, MD Anderson has been named one of the top two cancer hospitals, and it has ranked first 14 times in the last 17 years.
“MD Anderson is proud and grateful to be recognized once again as the leading cancer center in the nation, an honor that...
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement with a...
Almost one year after the U.S. Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children...